Regeneron Q2 Profit Tops Estimates, Revenue Rises 3.6%

Regeneron Pharmaceuticals reported Q2 earnings of $1.392 billion, beating estimates of $8.43 per share. Revenue rose 3.6% to $3.676 billion. CEO Leonard S. Schleifer attributed the strong quarter to growth in EYLEA HD, Dupixent, and Libtayo sales, as well as multiple regulatory approvals.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported its second-quarter (Q2) 2025 earnings, with the company posting a net income of $1.392 billion, surpassing analysts' estimates of $8.43 per share. Revenue for the quarter rose 3.6% to $3.676 billion, marking a significant improvement over the previous quarter's performance.

CEO Leonard S. Schleifer attributed the strong quarter to robust growth in EYLEA HD, Dupixent, and Libtayo sales, as well as multiple regulatory approvals. The company's EYLEA HD sales increased 29% to $393 million, while Dupixent global net sales rose 22% to $4.34 billion. Additionally, Libtayo's sales contributed to the overall revenue growth.

Regeneron also received several regulatory approvals during the quarter, including FDA approval for Lynozyfic (linvoseltamab) for relapsed or refractory multiple myeloma, and Dupixent for bullous pemphigoid and chronic spontaneous urticaria (CSU). These approvals are expected to drive future growth for the company.

The company's financial highlights include a 4% increase in total revenues, a 3% increase in GAAP net income, and a 12% increase in non-GAAP net income. The company also returned over $2.3 billion of capital to shareholders through share repurchases and dividends, and committed over $7 billion to U.S. manufacturing investments, capital expenditures, and business development since the start of 2025.

Looking ahead, Regeneron continues to prioritize its diverse pipeline, with approximately 45 product candidates in clinical development. The company is optimistic about the potential of its pipeline and expects additional data and regulatory milestones later this year.

References:
[1] https://finance.yahoo.com/news/regeneron-regn-q2-earnings-expect-030137811.html
[2] https://www.benzinga.com/analyst-stock-ratings/price-target/25/08/46785919/regeneron-pharmaceuticals-likely-to-report-lower-q2-earnings-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call
[3] https://www.manilatimes.net/2025/08/01/tmt-newswire/globenewswire/regeneron-reports-second-quarter-2025-financial-and-operating-results/2160685